Beate Beimea, Ralf Krügera, Gertrud Hammelb, Peter Bramlagea and Cornelia Deutscha
The aim of the present study was to validate the blood pressure (BP) measurement device, Microlife BP A3 PC, in patients with diabetes mellitus, according to the ANSI/AAMI/ISO 81060-2:2013 protocol.
In 85 individuals aged 56–88 years, with predefined criteria for diabetes mellitus, BP measurements on the upper arm were performed alternately using the Microlife BP A3 PC and a standard mercury reference sphygmomanometer. A total of 333 comparisons were included for analysis.
The mean difference between the Microlife BP A3 PC and the reference was −1.5± 6.3 mmHg for systolic BP (SBP) and −1.3± 5.2 mmHg for diastolic BP (DBP) according to criterion 1 of the protocol. For SBP, a total of 209 of the 333 measurements were within the range of 5 mmHg (62.8%), whereas the corresponding numbers for DBP were 232 of 333 (69.7%). For criterion 2, the intraindividual differences for the test device and the reference were −1.50± 4.73 mmHg for SBP and −1.30 ± 4.55 mmHg for DBP, thus being within the defined ranges provided by the protocol.
The Microlife BP A3 PC fulfilled the requirements of criteria 1 and 2 of the ANSI/AAMI/ISO 81060-2:2013 protocol and can also be recommended for BP measurement in diabetic patients.
Blood Press Monit 00:000–000 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.